Categories: News

Elixxer Ltd. Announces New Director

Montreal, Quebec–(Newsfile Corp. – November 26, 2021) – Elixxer Ltd. (TSXV: ELXR) (OTCQB: ELIXF) (the “Corporation” or “Elixxer“) is pleased to announce that Mr. Jeremy Green has been appointed to the Corporation’s board of directors. Mr. Green is replacing Mr. Jeff Cheah who has resigned due to health reasons.

Mr. Green’s career spans over twenty years in the banking industry. Until recently, he was senior director for online and mobile banking with a major Canadian chartered bank. Prior to that, he spent ten years with a competing Canadian chartered bank where he worked on numerous large scale retail banking projects, both in North America and in Europe. In addition, he has been a leading speaker on digital banking strategies at numerous industry conferences. Mr. Green holds a bachelor’s degree in administration from Simon Fraser University and an MBA in finance from Wilfrid Laurier University. Mr. Green’s appointment is subject to acceptance by the TSX Venture Exchange.

About Elixxer Ltd. (www.elixxer.com)

Elixxer Ltd. is a Canadian public company listed on the TSX Venture Exchange (TSXV: ELXR) and the US OTCQB exchange (OTCQB: ELXIF).

Through its partners, Elixxer presently has significant interests in Australia, Jamaica, Switzerland, Italy, and Canada.

For further information please contact:

Ferras Zalt, Chairman and Interim CEO: +44 20 7409 6680; Ferras@elixxer.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Notice Regarding Forward-Looking Statements

This press release may contain forward-looking statements with respect to Elixxer and its operations, strategy, investments, financial performance and condition. These statements can generally be identified by use of forward-looking words such as “may”, “will”, “expect”, “estimate”, “anticipate”, “intends”, “believe” or “continue” or the negative thereof or similar variations. The actual results and performance of Elixxer could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition, government regulation and the factors described under “Risk Factors and Risk Management” in Elixxer’s most recent Management’s Discussion and Analysis filed on SEDAR (www.sedar.com). The cautionary statements qualify all forward-looking statements attributable to Elixxer and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this press release, and Elixxer has no obligation to update such statements, except to the extent required by applicable securities laws

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/105215

Staff

Recent Posts

HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference

HeartBeam system was recently cleared by US Food and Drug Administration (FDA) for comprehensive arrhythmia…

2 hours ago

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused…

2 hours ago

The National Children’s Cancer Society Awarded $1,000 Grant From Kars4Kids

This generous grant will directly benefit the NCCS's Beyond the Cure Ambassador Scholarship Program, which…

2 hours ago

Honeycomb Clinic Positions for Public Offering

Medical Co-working space challenges broken healthcare system. HOUSTON, TEXAS / ACCESSWIRE / December 23, 2024…

2 hours ago

Ensysce Biosciences Regains Full Compliance with Nasdaq

SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"…

2 hours ago